December 2023

Malignidades en los ensayos clínicos de upadacitinib en la artritis reumatoide, la artritis psoriásica, la espondilitis anquilosante y la espondiloartritis axial no radiográfica

Rheumatol Ther 2023;11(1):97–112 doi 10.1007/s40744-023-00621-6

Rates of malignancy were similar between upadacitinib, adalimumab, and MTX. They were also consistent across RA, PsA, AS and nr-axSpA. A dose-dependent increased rate of NMSC was observed with upadacitinib in RA. For RA and PsA, being older (≥65 years) and male was associated with
an increased risk of malignancy excluding NMSC.

Keywords:

September 2023

The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel—A Retrospective Electronic Data-Based Study

J Clin Med. 2023;12(15):5153 doi: 10.3390/jcm12155153

Findings from a retrospective electronic data-based study, assessing risk of overall and site-specific malignancies for AS patients in Israel, emphasize the importance of maintaining the routine observation of patients with AS to identify the early development of cancer.

Keywords:

June 2023

Inhibidores JAK y el riesgo de malignidades: Un Meta-análisis en las Indicaciones de la terapia

Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049

The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.

Keywords:

March 2023

Seguridad de Baricitinib para los Eventos de Interés Especial en Poblaciones en Riesgo: Un análisis de Datos de Ensayos Aleatorizados en Indicaciones Reumatológicas y Dermatológicas

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

Riesgo de Malignidades con Tofacitinib frente a Inhibidores de TNF en Artritis Reumatoide: Resultados del Ensayo Abierto Aleatorizado Controlado ORAL Surveillance

Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543

Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.

Keywords: